耐草甘膦基因克隆和作物转化研究新进展

评述了耐草甘膦基因克隆和作物转化研究的新进展。生物耐草甘膦的机理主要在于1）过量表达EPSPS（磷酸烯醇式丙酮酰莽草酸合成酶）基因;2）EPSPS基因发生突变而对草甘膦的亲和力减弱。或3）解毒酶作用。现已从大肠杆菌、鼠伤寒沙门氏菌、矮牵牛、拟南芥、烟草、胡萝卜等中克隆了aroA等EPSPS基因并进行了分子生物学研究。作物转基因抗草甘膦育种主要通过三条途径;1）转入经过修饰的或突变的耐草甘膦EPSPS基因,2）转入过表达的EPSPS基因;3）导入草甘膦代谢酶基因。     

转(Bt Cry1Ac+CP_4EPSPS)基因抗虫抗草甘膦棉花对草甘膦的耐受性研究

本研究比较了转Bt Cry1Ac+CP_4EPSPS基因抗棉铃虫抗草甘膦棉花与常规棉花在新疆棉区对草甘膦的耐受性差异。两年的研究结果表明,转Bt Cry1Ac+CP_4EPSPS基因抗棉铃虫抗草甘膦棉花对草甘膦有较好的耐受性,而对照棉花中棉所49对草甘膦耐受性较差。苗期喷施草甘膦后转基因抗棉铃虫抗草甘膦棉花生长发育没有受到影响,而对照棉花中棉所49喷施草甘膦后生长发育受到了明显的影响,个别植株甚至死亡。转Bt Cry1Ac+CP_4EPSPS基因抗棉铃虫抗草甘膦棉花株高、真叶数、蕾数、产量等指标与对照相比差异显著。转Bt Cry1Ac+CP_4EPSPS基因棉花对草甘膦的耐受程度显著高于非转基因棉花。草甘膦对转基因抗草甘膦棉花无负面影响。     

油菜转抗草甘膦、抗虫基因获得双抗植株

以草甘膦为筛选剂,用农杆菌介导法将编码5-烯醇式丙酮酸莽草酸-3-磷酸合成酶（EPSPS）的aroA—M12基因和编码苏云金杆菌毒蛋白的Btslm基因导入到甘蓝型油菜优良品种湘油15号中。在用草甘膦对转化体进行筛选的基础上．对转基因再生植株进行了PCR检测、Southern blot和Western blot分析．结果证明外源基因确已导入到该油菜品种中,而且表达了相应的蛋白。对转基因植株进行抗草甘膦、抗虫性鉴定的结果表明．转基因植株具有抗草甘膦、抗虫的双重特性。研究结果还表明抗草甘膦的aroA—M12基因在植物基因转化中,既可以用作抗除草剂基因,又可以代替常用的抗生素标记,用作植物筛选标记基因。     

植物莽草酸途径EPSPS蛋白的分子进化和基因结构分析

EPSPS既是植物、微生物和真菌等生物芳香族氨基酸生物合成途径——莽草酸途径中的关键酶,也是除草剂草甘膦的靶标酶。EPSPS的克隆能为草甘膦抗性转基因作物的研发提供候选基因。该研究运用比较基因组学方法,通过对41种不同植物的43条EPSPS蛋白序列进行进化分析,取得主要结果如下:(1)不同植物EPSPS蛋白的相似性很高,且具有相同的结构域、保守基序和保守位点,但是其叶绿体转运肽序列差异显著;(2)系统发育分析表明,EPSPS基因按照双子叶植物纲和单子叶植物纲分为2个大的分支,各个小的分支又按照植物的种属亲缘关系进行分支和聚类;(3)基因结构分析表明,植物EPSPS基因基本都含有8个外显子和7个内含子,且所对应外显子的长度相当,而内含子的长度差异很大,说明在植物基因组进化过程中造成EPSPS基因结构差异的主要因素是内含子的改变。研究结果将为揭示植物EPSPS蛋白的结构功能提供参考。     

AM79 EPSPS蛋白的体外模拟胃肠液消化稳定性研究

AM79 EPSPS基因是从草甘膦高度污染的土壤中克隆的、具有我国自主知识产权的一个新型抗草甘膦基因,在转基因玉米中过表达能显著提高转基因玉米的草甘膦抗性,具有重要应用价值。为了评价AM79 EPSPS蛋白的食用安全性,本研究参考中华人民共和国国家标准,开展了AM79 EPSPS蛋白的消化稳定性研究。将AM79 EPSPS基因构建到原核表达载体pET-30a上,在大肠杆菌中表达了分子量为48.3 kD的可溶性AM79 EPSPS蛋白。通过Ni-NTA亲和层析方法纯化了AM79 EPSPS蛋白用于体外模拟胃肠液实验。结果表明,AM79 EPSPS蛋白在模拟胃肠液中均在15 s内即被消化,SDS-PAGE和Western蛋白免疫印迹均未检测到蛋白残留,表明AM79 EPSPS蛋白在模拟胃肠液体系中极易被消化。     

抗草甘膦转基因作物分子育种策略

杂草生长茂盛给农田经济造成了巨大的损失,而草甘膦的高效除草则有利于防治农业杂草。培育抗草甘膦作物也为农业杂草管治带来了便利。近年来,已从微生物、植物中均挖掘到了草甘膦抗性基因并用于开发抗草甘膦转基因作物,该文根据这些抗性基因作用的不同机制总结了抗草甘膦转基因作物的育种策略及其利弊,并对未来抗草甘膦作物的发展方向进行讨论。     

主要转基因作物研究现状及其产业化进展

经过12年的产业化发展,转基因作物研究取得了较大进展。相关外源基因的转入使抗虫、抗病、抗除草剂、抗逆、品质改良和功能性等作物相继问世。转基因大豆、玉米、棉花和油菜已经大面积种植,产生了极大的经济效益。2007年全球转基因作物的种植面积达到1．143亿hm^2。综述了主要转基因作物研究现状及其产业化进展,并对我国转基因作物产业化应解决的问题进行了论述。     

转基因抗草甘膦棉栽培地生存竞争能力

【目的】针对我国研发的具有自主知识产权的转EPSPS基因抗除草剂棉花,研究其环境适应和生存竞争能力,以评价其环境安全性,为其生产应用提供依据。【方法】试验在河南安阳中国农业科学院棉花研究所试验农场中进行。以转基因(EPSPS)抗草甘膦棉为试验品种,受体材料和中棉所49为对照品种,在正常管理模式下,对棉花的营养生长、生殖生长、产量因子及纤维品质等指标进行比较。【结果】转基因抗草甘膦棉花在苗期、现蕾期、花铃期和吐絮期的株高均低于受体材料,但差异不显著;花铃期,转基因抗草甘膦棉花每株花蕾数比受体材料少3.58个,差异达到显著水平;但在吐絮期其单株铃数比受体材料多1.1个,且其产量比受体材料高91.4 kg·hm~(-2);转基因抗草甘膦棉花的纤维品质也有一定程度的改善。同时,转基因抗草甘膦棉花上述各项生长指标、产量及纤维品质等均与对照品种中棉所49相当。【结论】转基因抗草甘膦棉花在栽培地环境下可正常生长,未对农业生产造成明显的负面影响和风险。     

主要农作物转化事件的专利保护及对我国的启示

作为转基因育种研究的核心技术成果,转化事件的知识产权保护为转基因作物产业化提供了重要的权利保障。目前世界主要农作物的转化事件绝大多数被孟山都、先正达、拜耳等国外公司所掌握,其中约有40%的转化事件正在全球申请同族专利保护,有22件已在我国申请,并且有6件已获得授权。国外转化事件专利的权利要求平均约20项,重点保护了侧翼序列和插入序列等关键技术特征,限制了任何未经许可而进行商业化改造或利用的可能。我国几乎还没有转化事件专利,"华恢1号"虽然比较接近,但保护强度不够。因此我国必须重点培育转化事件的自主知识产权,加强对国外专利的追踪分析,提高我国转化事件专利保护的精准度,最终构建知识产权全程保护体系。     

进口转基因抗草甘膦油菜籽和大豆中CP4—EPSPS基因的检测比较研究

由于国际上对转基因产品的安全性存在的较大争议,因此对没有加施标签予以声明的情况下大量进入中国市场的转基因产品进行检测就显得十分迫切且意义重大。本研究以进口转基因抗草甘膦油菜籽和大豆为材料,通过比较分析外源的CP4－EPSPS基因的核苷酸序列和表达的氨基酸序列,设计出两对不同的引物,采用PCR方法分别对转基因油菜籽和大豆中外源的CP4－EPSPS基因进行了检测。     

Freedom‐to‐operate analysis of a transgenic multivitamin corn variety

In this article, we explore the intellectual property (IP) landscape relevant to the production and commercialization of Carolight^?, a transgenic multivitamin corn variety created on humanitarian grounds to address micronutrient deficiencies in low‐and‐middle‐income countries. The successful production of this variety requires IP rights risk management because there is a strong protection on inventions and processes via patent portfolios in both developing and industrialized countries. The IP framework is complex, and specialist patent lawyers are usually employed to perform such analysis, but the costs cannot always be met by small, publicly funded projects. We report an alternative strategy, a do‐it‐yourself patent analysis, to produce a review with limited legal value that can nevertheless lay the foundations for a subsequent more in‐depth professional freedom‐to‐operate opinion.     

Intellectual property law: a primer for scientists

“Intellectual property” (IP) is a generic legal term for patents, copyrights, and trademarks, which provide legal rights to protect ideas, the expression of ideas, and the inventors and creators of such ideas. A patent provides legal protection for a new invention, an application of a new idea, discovery, or concept that is useful. Copyright provides legal protection from copying for any creative work, as well as business and scientific publications, computer software, and compilations of information. A trademark provides rights to use symbols, particular words, logos, or other markings that indicate the source of a product or service. A further method of benefiting from an invention is simply to keep it secret, rather than to disclose it—a “trade secret.” IP impinges on almost everything scientists do. As scientists are paid to come up with ideas and aspire to patent and/or publish their work, the protection of ideas and of written works especially should be of interest and concern to all.     

Antibody therapeutics - the evolving patent landscape

The antibody patent landscape has evolved dramatically over the past 30 years, particularly in areas of technology relating to antibody modification to reduce immunogenicity in humans or improve antibody function. In some cases antibody techniques that were developed in the 1980s are still the subject of patent protection in the United States or Canada.     

Intellectual property protection of plant biotechnology inventions

The intellectual property protection of biotechnology-related subject matter is undergoing significant change and several countries have revised their legislation and/or patent practice as a result of challenges from industry and members of the public. Plant-related subject matter can be protected using plant variety protection, utility patents or, in the USA, by plant patent. Although easier to obtain than a utility patent, plant variety protection does not provide the same scope of protection. Protecting a plant using a utility patent is permitted only in countries that allow the patenting of higher life forms and requires a higher degree of experimental support than is required for plant variety protection, although the scope of protection is being steadily reduced.     

农业生物技术领域专利态势分析

专利是技术的有效载体,通过专利态势分析可以在一定程度上有效掌握技术发展脉络及发展趋势。基于专利信息,采用定量数据、定性调研与专家智慧有机结合的方法,从申请趋势、保护市场、领域分布、重要专利权人等多维度分析视角进行农业生物技术领域专利技术态势分析。通过专利态势分析掌握全球农业生物技术专利保护概貌,指出重点方向。在此基础上结合中国农业生物技术领域专利法律状态和专利转让许可状况探讨中国农业生物技术专利保护现状及存在问题,以期支撑中国农业生物技术领域的创新决策。     

Influence of fasting on the effects of ischemic preconditioning in the ischemic-reperfused rat heart

The effects of fasting and ischemic preconditioning (IP) on heart function of Langendorff-perfused rat hearts exposed to 25 min global ischemia plus 30 min reperfusion (RP), were correlated with lactate release and tissue-levels of long-chain acyl carnitine (LCCa) and CoA (LCCoA). IP was achieved by a 3 min ischemia plus a 5 min reperfusion cycle. Creatine kinase leakage was measured to assess the extent of cardiac injury. Fasting reduced the ischemic-induced contracture, improved RP recovery of mechanical function, reduced lactate release and increased the end-ischemia LCCoA and LCCa levels. Both in the fed and the fasted rat hearts IP delayed the pacemaker depression, reduced the amplitude of ischemic contracture and improved the RP recovery of contraction. However, IP reduced creatine kinase and lactate release only in the fed rat hearts. IP had no effects on tissue LCCa and LCCoA in both groups. These data suggest that: 1) beneficial effects of fasting may be ascribed, at least in part, to a reduced lactate production which may attenuate ischemic myocyte acidification and to the accumulation of fatty acyl esters which would favour citric acid cycle replenishment during RP. 2) beneficial effects of IP could be in part explained by the reduction of lactate production in the fed group although data obtained with the fasted rat heart indicate that another mechanisms must also be involved in the effects of IP. 3) accumulation of LCCoA and LCCa is not involved in the noxious effects of ischemia as well as in the protection effected by IP.     

中国基因专利的数据挖掘

对中国专利基因数据库（NASDAP, http://nasdap.generank.org/）进行了统计和数据挖掘,展示了中国基因专利的全貌;揭示了我国基因专利申请的热点和薄弱面;通过对专利基因生命周期聚类结果的分析,总结出围绕一个专利基因进行二次创新的策略以及我国对此类申请的授权态度。这些数据挖掘结果可为我国药物开发和疾病诊断等生命科学高技术领域知识产权战略制定提供重要参考。     

HSP70.1 and -70.3 are required for late-phase protection induced by ischemic preconditioning of mouse hearts

We investigated the role of inducible heat shock proteins 70.1 and 70.3 (HSP70.1 and HSP70.3, respectively) in myocardial ischemic preconditioning (IP) in mice. Wild-type (WT) mice and HSP70.1- and HSP70.3-null [HSP70.1/3(-/-)] mice were subjected to IP and examined 24 h later during the late phase of protection. IP significantly increased steady-state levels of HSP70.1 and HSP70.3 mRNA and expression of inducible HSP70 protein in WT myocardium. To assess protection against tissue injury, mice were subjected to 30 min of regional ischemia and 3 h of reperfusion. In WT mice, IP reduced infarct size by 43% compared with sham IP-treated mice. In contrast, IP did not reduce infarct size in HSP70.1/3(-/-) mice. Absence of inducible HSP70.1 and HSP70.3 had no effect, however, on classical or early-phase protection produced by IP, which significantly reduced infarct size in HSP70.1/3(-/-) mice. We conclude that inducible HSP70.1 and HSP70.3 are required for late-phase protection against infarction following IP in mice.     

Protective immunity of Nile tilapia against Ichthyophthirius multifiliis post-immunization with live theronts and sonicated trophonts

Two immunization trials were conducted to evaluate host protection of Nile tilapia, Oreochromis niloticus against Ichthyophthirius multifiliis (Ich). Immunizations were done with live theronts or sonicated trophonts by bath immersion and intraperitoneal (IP) injection. The immunized fish were challenged with theronts 21 days post-immunization in trial I and 180 days post-immunization in trial II. The serum anti-Ich antibody and cumulative mortalities of tilapia were determined after theront challenge. Serum anti-Ich antibody was significantly higher (P<0.05) in tilapia immunized with live theronts by immersion or IP injection or with sonicated trophonts administered by IP injection than tilapia immunized with sonicated trophonts by immersion, with bovine serum albumin by IP injection, or non-immunized controls. Host protection was acquired in fish immunized with live theronts by immersion or IP injection. Tilapia immunized with sonicated trophonts by IP injection were partially protected with a 57-77% survival in both trials. At 180 days post-immunization, serum antibody titers had declined in immunized fish yet they were still able to survive challenge. The protection appears not to be solely depending on serum antibody response against Ich.